Thu. 22 Feb 2024, 7:50am ET
Benzinga
Earnings, News
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.91) by 5.49 percent. This is a 4.35 percent decrease over losses of $(0.92) per share from the same period last year. The company reported $1.75 million in sales this quarter. This is a 6.68 percent decrease over sales of $1.87 million the same period last year.